Phase 3 trial comparing Vectibix® (panitumumab) to Erbitux® (cetuximab) meets primary endpoint of non-inferiority of overall survival
28 September 2013 | By Amgen
Trial evaluated nearly 1,000 patients with metastatic colorectal cancer...
List view / Grid view
News
Japanese health authority approves SOVRIAD™ for the treatment of genotype-1 chronic HCV infection
27 September 2013 | By Johnson & Johnson
Japan is the first country in the world where SOVRIAD™ is approved...
IDegLira improves glycaemic control throughout the day with no weight gain and a low rate of hypoglycaemia
27 September 2013 | By Novo Nordisk
Data from the DUAL™ I trial show IDegLira demonstrates a statistically significant greater reduction in blood sugar levels (HbA1c) compared to insulin degludec or liraglutide alone...
New data for Novartis drug Lucentis® reinforces transformational efficacy and well-established safety profile across four indications
27 September 2013 | By Novartis
Pivotal myopic CNV trials with Lucentis® (ranibizumab) show visual acuity improvement of nearly 14 letters with a median of two injections at one year...
GSK and Barclays form partnership to increase access to healthcare and promote economic development in Zambia
27 September 2013 | By GlaxoSmithKline
GlaxoSmithKline (GSK) and Barclays have formed a new partnership which aims to increase access to affordable healthcare and medicines for people in Zambia...
Boehringer Ingelheim Animal Health achieves milestone: 500 million pigs benefit from Mycoplasma vaccination
27 September 2013 | By Boehringer Ingelheim
Boehringer Ingelheim announced today that veterinarians and farmers across the globe have reached the milestone of protecting more than 500 million pigs from the potentially devastating consequences of Mycoplasma hyopneumonia...
Marketing Authorisation Application for olaparib accepted by European Medicines Agency
27 September 2013 | By AstraZeneca
AstraZeneca today announced that the European Medicines Agency (EMA) has accepted its Marketing Authorisation Application (MAA) for olaparib...
Major study reveals new ways to classify cancer
27 September 2013 | By Cancer Research UK
A US-led initiative to map the molecular similarities and differences of thousands of tumours has revealed new ways to classify cancer...
Boehringer Ingelheim expands its production footprint in China
27 September 2013 | By Boehringer Ingelheim
Boehringer Ingelheim has inaugurated the building of its chemicals R&D laboratory Center of Competence in the Zhangjiang High-Tech Park in Shanghai...
Genzyme’s multiple sclerosis franchise featured at ECTRIMS
27 September 2013 | By Genzyme
18 platform and poster presentations provide deeper insight into the Clinical Development Programs for Aubagio® and Lemtrada™...
European Commission approves Gilead Sciences’ Tybost™
27 September 2013 | By Gilead Sciences, Inc.
Tybost™ is a new Bbosting agent for HIV therapy which facilitates once-daily dosing of the protease inhibitors Atazanavir and Darunavir...
Takeda submits new drug application in Japan for TAK-816
27 September 2013 | By Takeda Pharmaceutical Company Limited
TAK-816 is a Haemophilus Influenzae type b (Hib) vaccine...
EMA accepts AstraZeneca’s naloxegol marketing authorisation application
27 September 2013 | By AstraZeneca
Naloxegol is an investigational peripherally-acting mu-opioid receptor antagonist designed for the treatment of opioid-induced constipation (OIC)...
Teva presents new multiple sclerosis data 29th ECTRIMS Congress
27 September 2013 | By Teva Pharmaceutical Industries Ltd
Series of events throughout Congress to shed light on new data and evolving MS landscape...
Penn Pharma officially opens world leading contained manufacturing facility
26 September 2013 | By Penn Pharma
A £14 million state-of-the-art facility formally opened...
